PMID- 35165928
OWN - NLM
STAT- MEDLINE
DCOM- 20221007
LR  - 20221229
IS  - 1099-1069 (Electronic)
IS  - 0278-0232 (Print)
IS  - 0278-0232 (Linking)
VI  - 40
IP  - 4
DP  - 2022 Oct
TI  - Chidamide with PEL regimen (prednisone, etoposide, lenalidomide) for elderly or 
      frail patients with relapsed/refractory diffuse large B-Cell lymphoma -results of 
      a single center, retrospective cohort in China.
PG  - 617-625
LID - 10.1002/hon.2979 [doi]
AB  - Treatment for relapsed/refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL) is 
      evolving rapidly due to the emergence of novel drugs, of which histone 
      deacetylase inhibitors (HDACis) are an important example. This study showed 
      efficacy in patients with R/R DLBCL after failure of conventional therapies. We 
      conducted a single-center, retrospective study of 34 frail or elderly R/R DLBCL 
      patients who had been treated off-label with chidamide-containing regimens from 
      2018 to 2020. X(2) or Fisher test were used to compare response rate and 
      Kaplan-Meier method was used to perform the survival analyses which compared with 
      log-rank test between different groups. The test standard was p < 0.05. In total, 
      34 patients with R/R DLBCL received CPEL+/-R for at least 1 cycle were included. 
      Most of them were refractory patients (n = 28,82.4%). The interim objective 
      response rate (ORR) was 73.5% (32.4% complete remission [CR]), and the ultimate 
      ORR was 50.0% (35.3% CR). After a median follow-up of 13.1 months, the median 
      progression-free survival (PFS) was 10.5 months (95%CI 6.4-14.6) and the median 
      overall survival (OS) was 19.3 months (95%CI 11.8-26.9). The 1 year expected PFS 
      and OS rate was 43.0% and 73.7%, respectively. The most common grade 3/4 
      hematologic adverse events (AEs) were neutropenia (n = 11,32.3%) and anemia 
      (n = 4, 11.8%) 0.23.5% (8/34) of all patients experienced grade 3/4 
      nonhematologic AEs. No treatment-related deaths were observed. The study showed 
      chidamide-included regimen could be an option for R/R DLBCL patients ineligible 
      for intensive chemotherapies. Current data showed favorable efficiency and 
      moderate safety profile. Further study is warranted for better illustration of 
      efficacy and usage in combination therapies.
CI  - (c) 2022 The Authors. Hematological Oncology published by John Wiley & Sons Ltd.
FAU - Wang, Yawen
AU  - Wang Y
AUID- ORCID: 0000-0003-3623-9235
AD  - Department of Hematology, The Affiliated Hospital of Qingdao University, Qingdao, 
      China.
FAU - Xue, Hongwei
AU  - Xue H
AD  - Department of Hematology, The Affiliated Hospital of Qingdao University, Qingdao, 
      China.
FAU - Song, Wei
AU  - Song W
AD  - Department of Hematology, The Affiliated Hospital of Qingdao University, Qingdao, 
      China.
FAU - Xiao, Shuxin
AU  - Xiao S
AD  - Department of Hematology, The Affiliated Hospital of Qingdao University, Qingdao, 
      China.
FAU - Jing, Fanjing
AU  - Jing F
AD  - Department of Hematology, The Affiliated Hospital of Qingdao University, Qingdao, 
      China.
FAU - Dong, Tieying
AU  - Dong T
AD  - Department of Hematology, The Affiliated Hospital of Qingdao University, Qingdao, 
      China.
FAU - Wang, Lili
AU  - Wang L
AD  - Department of Pathology, The Affiliated Hospital of Qingdao University, Qingdao, 
      China.
LA  - eng
GR  - Y-HR2018-270/Beijing CSCO Clinical Oncology Research Foundation Programs/
PT  - Journal Article
DEP - 20220223
PL  - England
TA  - Hematol Oncol
JT  - Hematological oncology
JID - 8307268
RN  - 0 (Aminopyridines)
RN  - 0 (Benzamides)
RN  - 0 (Histone Deacetylase Inhibitors)
RN  - 4F4X42SYQ6 (Rituximab)
RN  - 6PLQ3CP4P3 (Etoposide)
RN  - 87CIC980Y0 
      (N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide)
RN  - F0P408N6V4 (Lenalidomide)
RN  - VB0R961HZT (Prednisone)
SB  - IM
MH  - Aged
MH  - Aminopyridines
MH  - Antineoplastic Combined Chemotherapy Protocols/adverse effects
MH  - Benzamides
MH  - Etoposide
MH  - Frail Elderly
MH  - Histone Deacetylase Inhibitors/therapeutic use
MH  - Humans
MH  - Lenalidomide
MH  - *Lymphoma, Large B-Cell, Diffuse/pathology
MH  - *Lymphoma, Non-Hodgkin/drug therapy
MH  - Prednisone/therapeutic use
MH  - Retrospective Studies
MH  - Rituximab
PMC - PMC9790240
OTO - NOTNLM
OT  - chidamide
OT  - histone deacetylase inhibitor
OT  - refractory/relapsed diffuse large B-cell lymphoma
OT  - retrospective study
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2022/02/16 06:00
MHDA- 2022/10/12 06:00
PMCR- 2022/12/25
CRDT- 2022/02/15 05:39
PHST- 2021/10/03 00:00 [received]
PHST- 2022/02/10 00:00 [accepted]
PHST- 2022/02/16 06:00 [pubmed]
PHST- 2022/10/12 06:00 [medline]
PHST- 2022/02/15 05:39 [entrez]
PHST- 2022/12/25 00:00 [pmc-release]
AID - HON2979 [pii]
AID - 10.1002/hon.2979 [doi]
PST - ppublish
SO  - Hematol Oncol. 2022 Oct;40(4):617-625. doi: 10.1002/hon.2979. Epub 2022 Feb 23.